Sign in

    James Nevin • RBC Capital Markets

    James Nevin is an experienced Equity Research Analyst who worked at RBC Securities Australia Pty Ltd. (RBC Capital Markets) from 2020 to 2021, covering companies in Australia's energy sector, notably providing analytical coverage during significant events such as Infigen Energy's $535 million takeover bid by Ayala Corporation. During his time as lead analyst at RBC, Nevin demonstrated a rigorous approach to equity research and delivered actionable insights to institutional clients, leveraging his skills as both a CFA charterholder and FCA. Prior to RBC, he accumulated several years of equity research experience and later transitioned to BlackRock, where he continued his analytical work and contributed to event-driven and liquid alternatives strategies. Nevin is recognized for his professional credentials, including being a Fellow of the Institute of Chartered Accountants in England and Wales (FCA) and holding the Chartered Financial Analyst (CFA) designation.

    James Nevin's questions to Mind Medicine (MindMed) Inc (MNMD) leadership

    James Nevin's questions to Mind Medicine (MindMed) Inc (MNMD) leadership • Q4 2024

    Question

    James Nevin of RBC Capital Markets inquired about early enrollment rates for the GAD trials compared to Phase II, the potential impact of increased psychedelic awareness on expectancy bias, and a perceived discrepancy in exclusion criteria for bipolar disorder between the Voyage and Panorama trial listings.

    Answer

    CEO Robert Barrow reported encouraging early enrollment trends but did not provide specific numbers, stating the patient population is expected to be very similar to the Phase IIb trial. He acknowledged that expectancy bias is inherent in late-stage trials but is accounted for in their robust design. He also clarified that the inclusion/exclusion criteria, including for bipolar disorder, are consistent across both studies.

    Ask Fintool Equity Research AI